Onconetix (ONCO) Research & Development (2021 - 2026)
Onconetix (ONCO) posted quarterly Research & Development of $50818.0 for Q1 2026, up 107.8% year-over-year from $24455.0 in Q1 2025, and up 109.19% quarter-over-quarter from $24293.0 in Q4 2025.
Onconetix (ONCO) Research & Development (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Research & Development for 6 consecutive years, with $50818.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 107.8% year-over-year to $50818.0; the TTM figure through Mar 2026 stood at -$39770.0 (down 130.63% YoY), while the FY2025 annual figure was -$66133.0, down 142.84% from the prior year.
- Research & Development advanced to $50818.0 in Q1 2026 per ONCO's latest filing, from $24293.0 in the prior quarter.
- Across five years, Research & Development topped out at $1.3 million in Q2 2022 and bottomed at -$198921.0 in Q4 2023.
- Historically, Research & Development has averaged $365773.0 across 5 years, with a median of $50818.0 in 2026.
- On a YoY basis, Research & Development climbed as much as 8476.9% in 2025 and fell as far as 2934.51% in 2025.
- Onconetix's Research & Development stood at $1.2 million in 2022, then sank by 116.5% to -$198921.0 in 2023, then soared by 99.85% to -$290.0 in 2024, then jumped by 8476.9% to $24293.0 in 2025, then soared by 109.19% to $50818.0 in 2026.
- Business Quant data shows ONCO's Research & Development at $50818.0 in Q1 2026, $24293.0 in Q4 2025, and -$3211.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 97.90 Mn |
| 10 | Onconetix | 1.45 Mn | -4.49 Mn | 4,303.00 | 3,440.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,440.00 |
| Mar 31, 2026 | 50,818.00 |
| Dec 31, 2025 | 24,293.00 |
| Sep 30, 2025 | -3,211.00 |
| Jun 30, 2025 | -111,670.00 |
| Mar 31, 2025 | 24,455.00 |
| Dec 31, 2024 | -290.00 |
| Sep 30, 2024 | 109,365.00 |
| Jun 30, 2024 | -3,680.00 |
| Mar 31, 2024 | 48,964.00 |
| Dec 31, 2023 | -198,921.00 |
| Sep 30, 2023 | 219,238.00 |
| Jun 30, 2023 | 846,853.00 |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.18 Mn |
| Jun 30, 2022 | 1.29 Mn |
| Mar 31, 2022 | 455,092.00 |
| Dec 31, 2021 | 437,326.00 |
| Sep 30, 2021 | 269,925.00 |